162 related articles for article (PubMed ID: 35322192)
41. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
[TBL] [Abstract][Full Text] [Related]
42. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
43. LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.
Layer JH; Alford CE; McDonald WH; Davé UP
Mol Cell Biol; 2016 Feb; 36(3):488-506. PubMed ID: 26598604
[TBL] [Abstract][Full Text] [Related]
44. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
45. LMO2 at 25 years: a paradigm of chromosomal translocation proteins.
Chambers J; Rabbitts TH
Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
[TBL] [Abstract][Full Text] [Related]
46. T-ALL can evolve to oncogene independence.
Abdulla H; Vo A; Shields BJ; Davies TJ; Jackson JT; Alserihi R; Viney EM; Wong T; Yan F; Wong NC; Demoen L; Curtis DJ; Alexander WS; Van Vlierberghe P; Dickins RA; McCormack MP
Leukemia; 2021 Aug; 35(8):2205-2219. PubMed ID: 33483615
[TBL] [Abstract][Full Text] [Related]
47. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
Hirose K; Inukai T; Kikuchi J; Furukawa Y; Ikawa T; Kawamoto H; Oram SH; Göttgens B; Kiyokawa N; Miyagawa Y; Okita H; Akahane K; Zhang X; Kuroda I; Honna H; Kagami K; Goi K; Kurosawa H; Look AT; Matsui H; Inaba T; Sugita K
Blood; 2010 Aug; 116(6):962-70. PubMed ID: 20519628
[TBL] [Abstract][Full Text] [Related]
48. The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
Shields BJ; Slape CI; Vo N; Jackson JT; Pliego-Zamora A; Ranasinghe H; Shi W; Curtis DJ; McCormack MP
Leukemia; 2019 Aug; 33(8):1868-1880. PubMed ID: 30700838
[TBL] [Abstract][Full Text] [Related]
49. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
[TBL] [Abstract][Full Text] [Related]
50. Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia.
Cleveland SM; Smith S; Tripathi R; Mathias EM; Goodings C; Elliott N; Peng D; El-Rifai W; Yi D; Chen X; Li L; Mullighan C; Downing JR; Love P; Davé UP
Stem Cells; 2013 May; 31(5):882-94. PubMed ID: 23378057
[TBL] [Abstract][Full Text] [Related]
51. The LMO2 oncogene regulates DNA replication in hematopoietic cells.
Sincennes MC; Humbert M; Grondin B; Lisi V; Veiga DF; Haman A; Cazaux C; Mashtalir N; Affar el B; Verreault A; Hoang T
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1393-8. PubMed ID: 26764384
[TBL] [Abstract][Full Text] [Related]
52. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
[TBL] [Abstract][Full Text] [Related]
53. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P; van Grotel M; Beverloo HB; Lee C; Helgason T; Buijs-Gladdines J; Passier M; van Wering ER; Veerman AJ; Kamps WA; Meijerink JP; Pieters R
Blood; 2006 Nov; 108(10):3520-9. PubMed ID: 16873670
[TBL] [Abstract][Full Text] [Related]
54. Conditional Immortalization of Lymphoid Progenitors via Tetracycline-Regulated
Koniaeva E; Stahlhut M; Lange L; Sauer MG; Kustikova OS; Schambach A
Hum Gene Ther; 2020 Feb; 31(3-4):183-198. PubMed ID: 31760808
[TBL] [Abstract][Full Text] [Related]
55. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
Lossos C; Bayraktar S; Weinzierl E; Younes SF; Hosein PJ; Tibshirani RJ; Sutton Posthumus J; DeAngelis LM; Raizer J; Schiff D; Abrey L; Natkunam Y; Lossos IS
Br J Haematol; 2014 Jun; 165(5):640-8. PubMed ID: 24571259
[TBL] [Abstract][Full Text] [Related]
56. Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Venkitachalam S; Chueh FY; Yu CL
Biochem Biophys Res Commun; 2012 Jan; 417(3):1058-62. PubMed ID: 22222369
[TBL] [Abstract][Full Text] [Related]
57. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
[TBL] [Abstract][Full Text] [Related]
58. Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia.
Hoang T
Sci Transl Med; 2010 Mar; 2(21):21ps10. PubMed ID: 20374994
[TBL] [Abstract][Full Text] [Related]
59. LMO2 Enhances Lamellipodia/Filopodia Formation in Basal-Type Breast Cancer Cells by Mediating ARP3-Profilin1 Interaction.
Liu Y; Wu C; Zhu T; Sun W
Med Sci Monit; 2017 Feb; 23():695-703. PubMed ID: 28170369
[TBL] [Abstract][Full Text] [Related]
60. MiR-223 Suppresses Proliferation and Promotes Apoptosis of Diffuse Large B-Cell Lymphoma Cells Through Lmo2 and MAPK Signaling Pathway.
Zhang Y; Zhang J
J BUON; 2021; 26(2):580-586. PubMed ID: 34077008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
